Evidence map›Paper›PMID 35991586›Full record

ArticleThe neuroscience chronicles2020

MicroRNA silencing: A promising therapy for Alzheimer's disease.

Neelima B Chauhan

Open access · greenAbstract read
In one paragraph

Article in The neuroscience chronicles, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Neelima B ChauhanDepartment of Pharmaceutical Sciences, School of Pharmacy, American University of Health Sciences, Signal Hill, CA 90755, United States.
American University of Health Sciences · US

Funding

Therapeutic Efficacy of Intranasal WGA-GLP1 in ADR21NS079614 · NINDS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CHAUHAN, NEELIMA · 2013 to 2014
$437k
WGA as a Novel Vehicle for Intranasal Delivery of an Anti-A-beta Antibody in ADR21AG039625 · NIA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CHAUHAN, NEELIMA · 2011 to 2012
$373k
NIA NIH HHS R21 AG039625NINDS NIH HHS R21 NS079614RRD VA I01 RX000880
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a global health crisis currently afflicting ~6 million Americans (and ~40 million people worldwide). By the middle of the century, these numbers will stagger by ~16 million Americans (and ~152 million people worldwide) suffering from AD, if breakthrough disease-modifying treatments are not discovered. Currently, there are no treatments to prevent, halt or cure the disease. Multiple independent studies on brain gene expression patterns have indicated that in AD about 1/3

Indexed as

Alzheimer’s diseaseAntagomiRsMicroRNANeuroinflammation

Identifiers

PMID35991586
PMCPMC9389881
OpenAlexW4251655876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.